Dynegy Inc. Buyback
OLI recorded this information on 8/6/2015
In connection with the Company's financial outlook, the continuing reduction in generation supply, and the overall decline of equities in the commodity and power sector, Dynegy's Board of Directors has authorized a share repurchase program accelerating the Company's capital allocation plans. The share repurchase program for up to $250 million is being initiated in the third quarter of 2015 with targeted completion in 2016.
Dyne Therapeutics is a muscle disease company focused on advancing innovative life-transforming therapeutics for patients with genetically driven diseases. Co. offers its services in the United States.
DYN SEC Filing Email Alerts Service
Open the DYN Page at The Online Investor »
Strong Buy (4.00 out of 4)
(ranked higher than approx. 93% of all stocks covered)
Based on Zacks ABR data;
powered by Xignite